AMBRISENTAN
| Brand name | LETAIRIS |
|---|---|
| Active ingredient | AMBRISENTAN |
| Strength | 5MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | June 2007 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9549926 | October 2031 | use U-1965 |
| 9474752 | December 2027 | use U-1754 |
| 8377933 | December 2027 | use U-1754 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.